Hospital
Harrison Community Hospital, INC.
Harrison Community Hospital, INC. was paid $4.66M by Medicaid between Jan 2018 and Dec 2024, across 114 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoHARRISON COMMUNITY HOSPITAL, INC.
CADIZ, OH 43907
CADIZ, OH 43907
33aNPI1134151137assigned 07/07/2006
33bProvider typeCritical Access Hospital
28Total paid$4.66M
24GClaims102,537
24DCodes billed114
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Ohio
Rank by total paid#16 of 26
Median peer was paid$5.33M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,277 | $428K | |
| 2019 | 9,565 | $377K | |
| 2020 | 8,366 | $511K | |
| 2021 | 7,655 | $430K | |
| 2022 | 8,484 | $481K | |
| 2023 | 31,291 | $1.21M | |
| 2024incomplete | 25,899 | $1.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 11,587 | 9,105 | $1.12M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 20% | 15,237 | 10,548 | $952K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 5,466 | 4,129 | $580K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 13,640 | 9,656 | $546K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.7% | 4,959 | 3,821 | $310K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.4% | 3,198 | 2,773 | $160K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.3% | 1,102 | 775 | $152K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 396 | 332 | $131K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 273 | 211 | $95K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.0% | 300 | 221 | $91K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 184 | 117 | $80K |
| 80053 | Comprehensive metabolic panel | 1.2% | 4,658 | 3,655 | $56K |
102 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 291 | $46K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 527 | $32K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,502 | $26K |
| 62323 | <1% | 194 | $24K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 386 | $20K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 327 | $20K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,417 | $19K |
| 80061 | Lipid panel | <1% | 1,495 | $19K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 364 | $16K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 226 | $16K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,281 | $15K |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,662 | $14K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 567 | $13K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 88 | $11K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 510 | $10K |
| 99406 | <1% | 365 | $10K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,404 | $9K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 860 | $8K |
| 82607 | <1% | 307 | $5K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 127 | $5K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 17 | $4K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 75 | $4K |
| 99442 | <1% | 167 | $3K | |
| 73630 | <1% | 147 | $3K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,328 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 379 | $2K |
| 81001 | <1% | 1,668 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 29 | $2K |
| 85610 | <1% | 875 | $2K | |
| 83735 | <1% | 637 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 788 | $2K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 43 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 776 | $1K |
| 84439 | <1% | 62 | $1K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 54 | $1K |
| 85027 | <1% | 252 | $1K | |
| 84484 | <1% | 1,139 | $1K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 96 | $1K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 29 | $1K |
| A0425 | Ground mileage, per statute mile | <1% | 129 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 448 | $926.05 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 17 | $900.68 |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 59 | $887.26 |
| 90686 | <1% | 31 | $787.35 | |
| 82570 | <1% | 88 | $744.67 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 37 | $732.71 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 38 | $700.23 |
| 83605 | <1% | 835 | $690.20 | |
| 72110 | <1% | 28 | $643.93 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 193 | $574.14 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,029 | $543.75 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 34 | $539.24 |
| G0378 | Hospital observation service, per hour | <1% | 33 | $487.96 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 16 | $483.82 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 800 | $448.13 |
| 83690 | <1% | 1,088 | $394.37 | |
| 99441 | <1% | 52 | $384.21 | |
| 83880 | <1% | 272 | $374.41 | |
| 81025 | <1% | 286 | $357.29 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 17 | $333.15 |
| 85007 | <1% | 51 | $311.63 | |
| 73130 | <1% | 16 | $298.21 | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 69 | $282.09 |
| 90656 | <1% | 25 | $268.70 | |
| 85730 | <1% | 466 | $258.40 | |
| 86803 | <1% | 27 | $243.01 | |
| 82043 | <1% | 51 | $225.08 | |
| 82962 | <1% | 51 | $220.98 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 185 | $200.08 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 292 | $147.69 |
| 99305 | <1% | 17 | $135.84 | |
| 73610 | <1% | 29 | $135.66 | |
| 87807 | <1% | 48 | $87.60 | |
| 80305 | <1% | 35 | $74.22 | |
| G0008 | Administration of influenza virus vaccine | <1% | 30 | $74.04 |
| 83540 | <1% | 17 | $73.20 | |
| 87077 | <1% | 41 | $69.10 | |
| J3490 | Unclassified drugs | <1% | 41 | $60.00 |
| 86618 | <1% | 18 | $55.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 684 | $22.84 |
| 86140 | <1% | 13 | $21.97 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 110 | $21.07 |
| 87186 | <1% | 26 | $17.27 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 46 | $16.16 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 619 | $10.58 |
| 87081 | <1% | 27 | $8.08 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 14 | $7.83 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 35 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 33 | $0.00 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 49 | $0.00 |
| 87400 | 0% | 24 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 17 | $0.00 |
| 87040 | 0% | 16 | $0.00 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 114 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 88 | $0.00 |
| 85379 | 0% | 16 | $0.00 | |
| A0427 | Emergency ambulance ride, advanced life support | 0% | 15 | $0.00 |
| A9270 | Non-covered item or service | 0% | 15 | $0.00 |
| 84703 | 0% | 15 | $0.00 | |
| 98967 | 0% | 30 | $0.00 | |
| 82803 | 0% | 13 | $0.00 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPHILLIPS, DAVID (PRESIDENT & CEO)
| Provider | Location | Paid |
|---|---|---|
| ST John Sapulpa, INC. | Sapulpa, OK | $6.85M |
| Owasso Medical Facility, INC | Owasso, OK | $3.35M |
| Barnesville Hospital Association, INC. | Barnesville, OH | $3.14M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.